Order your MiniSeq reagents and library prep kits together for additional savings and convenience. Select item 20005612 and add to your cart.
Developed in collaboration with cancer genomics experts, these predesigned, ready-to-use oligos enable researchers to sequence a variety of genes and single nucleotide polymorphisms (SNPs) previously linked to cancer predisposition.
TruSight Cancer includes genes associated with both common (e.g., breast, colorectal) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert curation of the scientific literature and other high-quality resources.
The TruSight Cancer sequencing panel provides custom oligos targeting identified regions of interest. Sufficient product is supplied for four enrichment reactions. TruSight Cancer is compatible with TruSight Rapid Capture.
6 human reference samples were prepared using the TruSight Cancer sequencing panel. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 100 bp read length configuration with dual indexing. The total yield was 5.2 Gb with 95.8% of bases at or above Q30.
* Note that access to this data requires a BaseSpace Sequence Hub login.
Register for BaseSpace Sequence Hub
See All Illumina Cancer Research Panels
This product is available as an Illumina Advantage (TG) product. Illumina Advantage large-scale sequencing products feature lot-specific shipments and testing, extended shelf life, and advanced change notifications for greater laboratory efficiency.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| MiniSeq System | Samples per run: mid output: 12, high output: 24 (based on > 20x coverage per target) | Up to 2 × 150 bp |
| MiSeq System | Samples per run (by reagent kit version): v2: 12, v3: 24 (based on > 20x coverage per target) | Up to 2 × 150 bp |
| NextSeq 550 System | Samples per run: mid output: 96, high output: 96 (based on > 20x coverage per target) | Up to 2 × 150 bp |
| TruSight Cancer | AmpliSeq for Illumina BRCA Panel | |
|---|---|---|
| Assay Time | 1.5 days | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) |
| Cancer Type | Pan-Cancer | Solid Tumor |
| Content Specifications | Fixed set of probes that enrich for 94 genes and 284 SNPs associated with common and rare cancers. | Exonic regions and the flanking intronic sequences of the BRCA1 and BRCA2 |
| Description | Germline mutation detection research for common and rare cancers. | Germline and somatic analysis studies of BRCA1 and BRCA2. |
| Hands-On Time | 5 hours | < 1.5 hours |
| Input Quantity | 50 ng DNA | 1–100 ng (10 ng recommended per pool) |
| Method | Target Enrichment, Targeted DNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing |
| Multiplexing | Up to 96-plex | 96 dual index combinations |
| Specialized Sample Types | Not FFPE-Compatible | Blood, FFPE Tissue |
| Species Category | Human | Human |
| Variant Class | Germline Variants | Germline Variants, Insertions-Deletions (indels), Single Nucleotide Polymorphisms (SNPs), Somatic Variants |
Researchers from the MGZ Medical Genetic Center are using the Infinium CytoSNP-850K BeadChip and the TruSight Cancer Panel to analyze chromosomal abnormalities.
Read Moreproduct_file | EXCEL < 1 MB
Data Sheet | PDF < 1 MB
TruSight Rapid Capture Kit Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted panel investigating the exonic regions of 409 genes with known associations to cancer.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
These sequencing reagent kits offer increased stability and robustness over the v2 kit version.
Prepare sequencing libraries for small genomes, PCR amplicons, plasmids, or cDNA in as little as 90 minutes, with a low DNA input requirement.
Tailor panel designs for human disease research efficiently and conveniently by selecting from a catalog of over 5,000 pretested genes.
Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.
Note regarding biomarker patents and other patents unique to specific uses of products:
Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.
